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Available online 9 July 2016Background. Serum uric acid level is a predictor of future hypertension. However, its dependence on body
mass index or age is unclear.
Methods.Weexamined 26,442 Japanesemales aged 18–60 years free fromhypertension or diagnosed cardio-
vascular disease at baseline followedup between 2000 and 2010. Participantswere categorized into three groups
according to the tertile of serum uric acid levels [mg/dL; 1st (reference): 0.1–5.3; 2nd: 5.4–6.2; 3rd: 6.3–11.6].
Incident hypertension was deﬁned as newly detected blood pressure ≥ 140/90 mm Hg and/or antihypertensive
drugs initiation. Body mass index (b25 kg/m2 vs. ≥25 kg/m2) and age (b40 years vs. ≥40 years) were stratiﬁed
into two groups.
Results. During a mean follow-up of 7.2 years, there were 11,361 (43%) hypertension cases. Mean serum uric
acid levels (mg/dL) at baseline in each group were 1st tertile, 4.6; 2nd tertile, 5.8; and 3rd tertile, 7.0. The cumu-
lative incident hypertension rate was signiﬁcantly higher in the 3rd tertile (50.8%) than in the 1st (37.4%). Mul-
tiple-adjusted hazard ratios (95% conﬁdence interval) for incident hypertension compared with 1st tertile were
1.01 (0.96–1.05) and 1.15 (1.10–1.21) in the 2nd and 3rd tertile, respectively. There was a signiﬁcant interaction
between age and serum uric acid level (p for interaction= 0.035). In subjects aged ≥40 years, the 3rd serum uric
acid group showed higher hazard ratios [1.48 (1.38–1.59)].
Conclusion. High serum uric acid level was associated with future hypertension in young and middle-aged
Japanese males. This association was stronger among subjects ≥40 years old.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Uric acid1. Introduction
Hypertension is one of the most important risk factors of stroke, car-
diovascular disease, and renal disease, and the risk of morbidity and
death increases as blood pressure exceeds the optimal levels (Fujiyoshi
et al., 2012; Imano et al., 2009; Kondo et al., 2013; Okumura et al.,
2014; Tozawa et al., 2003). However, approximately 90% hypertension
cases are of essential hypertension, and the etiology of its onset is unclear
(Anderson et al., 1994; Omura et al., 2004; Rossi et al., 2006).
Uric acid (UA) is theﬁnalmetabolite of purines in human and increas-
ing serum UA (SUA) levels are known to be associated with incident hy-
pertension (Forman et al., 2009; Grayson et al., 2011; Krishnan et al.,index; UA, uric acid; HR, hazard
itric oxide.
Medicine in Cardiopulmonary
, Nagoya, Japan; 65 Tsurumai-
o).
. This is an open access article under2007; Mellen et al., 2006; Nakanishi et al., 2003; Taniguchi et al., 2001).
Some studies have shown that blood pressure is lowered by UA-lowering
drugs (Agarwal et al., 2013; Feig et al., 2008; Soletsky and Feig, 2012).
However, there is insufﬁcient data regarding whether SUA level is an in-
dependent risk factor of incident hypertension and the subgroup that is
associated with incident hypertension (Wu et al., 2016).
We conducted a large-scale long-term cohort study to investigate
the relationships of SUA levels and incident hypertension and of sub-
groups associated with incident hypertension in young and middle-
aged Japanese males free from hypertension or diagnosed cardiovascu-
lar disease at baseline. This studywas approved by the ethics committee
of the Nagoya University School of Medicine and all subjects gave their
informed consent for participation.
2. Methods
2.1. Study population
The subjects were 33,942 Japanese maleworkers aged 18–60 years, recruit-
ed in 2000, who underwent annual medical checkups at their workplaces fromthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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workers in Japan, and none of them refused to participate. All subjects were
employed by blue chipmanufacturing companies in Aichi Prefecture, in the cen-
ter of Japan. We excluded subjects with only baseline data (n= 769); with hy-
pertension (≥140/90mmHg and/or taking antihypertensive drugs (n= 4223);
who were taking drugs for hyperuricemia (n = 953), heart disease (n = 191),
renal disease (n = 122), lipid abnormalities (n = 1965), and diabetes mellitus
(n = 761). The ﬁnal sample was 26,442 subjects (Fig. 1).
2.2. Examination
Annual medical checkups were performed from 2000 until 2010 or retire-
ment and included physical examination, blood pressure measurement, blood
test, dipstick urine test, and structured questionnaire. The questionnaire com-
prised smoking status, alcohol intake, medical history, and medications. The
smoking status was classiﬁed into three groups (current smoker, former smok-
er, and never smoker), and alcohol intakewas classiﬁed into two groups (habit-
ual and non-habitual). A habitual drinker was deﬁned as a subject who drank
alcohol every day. Weight and height were measured while the subject was
wearing light clothing and no shoes. The body mass index was computed as
the weight in kilograms divided by the square of the height in meters. Blood
and urine test samples were collected in the morning after fasting for 1 night.
Blood samples were analyzed using autoanalyzer (Dimension RxL MAX; SIE-
MENS,Munich, Germany) andmeasured by the uricase ultravioletmethod. Uri-
nalysis was performed using a dipstick. Urinalysis for proteinuria was
conducted using Uropaper III (Eiken Chemical Co., Ltd., Tokyo, Japan), and the
results were measured using a US-2100 Automated Urine Analyzer (Eiken
Chemical Co., Ltd., Tokyo, Japan) [trace (±), proteinuria ≥15 mg/dL; 1+,
≥30 mg/dL; 2+, ≥100 mg/dL; 3+, ≥300 mg/dL; 4+, ≥1000 mg/dL].
2.3. Blood pressure measurement
Blood pressure was measured annually with the participant in the sit-
ting position after a 5-min rest using an automated sphygmomanometerFig. 1. Flow of study participant selection. Pre existing hypertension was deﬁned as blood pres(BP-203IIIB; Colin Corporation, Tokyo, Japan). The blood pressure was mea-
sured twice on the right arm with intervals of 1 min, and the average value
was calculated as the baseline blood pressure. When a subject had frequent
premature contractions or atrial ﬁbrillation, trained nurses conﬁrmed the
blood pressure using a conventional mercury sphygmomanometer. Incident
hypertension was deﬁned as that when the newly detected blood pressure
was higher than 140/90 mm Hg and/or when antihypertensive drugs were
initiated.2.4. Statistical analysis
Statistical analyses were performed using the STATA software program ver-
sion 11 (Stata Corp. College Station, TX, USA). Subjects were classiﬁed into
tertiles on the basis of the SUA levels at the baseline. In the analyses, we used
the lowest tertile of SUA as a reference group. Proteinuria was classiﬁed into
three groups: negative (−), trace (±), and ≥1+. Baseline characteristics were
analyzed using the trend test according to the tertile of SUA level (Table 1). Ac-
cording to the presence of incident hypertension, continuous variables were
compared using t-test, and categorical variables were compared using a chi-
square test (Table 2).
The Kaplan–Meier method was used to create the survival curves for each
group and compared using the log-rank test. Cox proportional hazards model
was used to calculate adjusted hazard ratio (HR) of incident hypertension ac-
cording to the tertile of SUA level in ﬁve models. Model 1 was crude, model 2
was further adjusted for age, model 3 was further adjusted for BMI, model 4
was further adjusted for systolic blood pressure of baseline, and lastly, model
5 was further adjusted for total cholesterol, triglyceride, fasting blood glucose,
creatinine, urine protein, smoking history, and alcohol intake.
In subgroup analysis, we stratiﬁed age (≥40 years and b40 years) and BMI
(≥25 kg/m2 and b25 kg/m2) and also performed the test of interaction using
likelihood ratio test. Cut-off value of BMI was decided as per the Japanese deﬁ-
nition of obesity (Chin and Miyazaki, 2009). All p values were two tailed, and
p b 0.05 were considered statistically signiﬁcant.sure ≥ 140/90 mm Hg and/or use of antihypertensive drugs. SUA denotes serum uric acid.
Table 1
Baseline characteristics according to the tertile of SUA concentration.
All
Baseline SUA tertile (mg/dL)
p for trend
0.1–5.3
(Mean, 4.6)
5.4–6.2
(Mean, 5.8)
6.3–11.6
(Mean, 7.0)
Number of participants 26,442 8926 8935 8581
Age (years) 36.8 ± 8.7 36.9 ± 8.9 36.4 ± 8.6 37.1 ± 8.5 0.071
Body mass index (kg/m2) 22.5 ± 2.8 21.7 ± 2.6 22.3 ± 2.7 23.5 ± 2.9 b0.001
Systolic blood pressure (mm Hg) 113.9 ± 10.3 112.7 ± 10.4 113.8 ± 10.3 115.2 ± 10.1 b0.001
Diastolic blood pressure (mm Hg) 69.1 ± 9.4 68.0 ± 9.3 68.8 ± 9.2 70.6 ± 9.4 b0.001
Total cholesterol (mg/dL) 189.1 ± 31.3 184.1 ± 30.2 187.8 ± 30.9 195.7 ± 31.7 b0.001
HDL cholesterol (mg/dL) 56.9 ± 13.6 58.0 ± 13.5 57.1 ± 13.5 55.5 ± 13.7 b0.001
Triglyceride (mg/dL) 116.2 ± 75.8 103.6 ± 62.4 112.4 ± 73.3 133.2 ± 87.0 b0.001
Creatinine (mg/dL) 0.93 ± 0.11 0.91 ± 0.10 0.93 ± 0.10 0.96 ± 0.11 b0.001
Fasting blood glucose (mg/dL) 90.2 ± 12.5 89.5 ± 13.8 89.8 ± 12.0 91.3 ± 11.6 b0.001
Dipstick proteinuria
Negative 25,922 (98.0%) 8767 (98.2%) 8770 (98.2%) 8385 (97.7%)
Trace 177 (0.7%) 65 (0.7%) 55 (0.6%) 57 (0.7%)
≥1+ 343 (1.3%) 94 (1.1%) 110 (1.2%) 139 (1.6%) 0.016
Smoker
Never 6878 (26.0%) 2199 (24.6%) 2319 (26.0%) 2360 (27.5%)
Former 4938 (18.7%) 1490 (16.7%) 1631 (18.3%) 1817 (21.2%)
Current 14,626 (55.3%) 5237 (58.7%) 4985 (55.8%) 4404 (51.3%) b0.001
Alcohol intake
Habitual 9538 (36.1%) 2649 (29.7%) 3181 (35.6%) 3708 (43.2%)
Non-habitual 16,904 (63.9%) 6277 (70.3%) 5754 (64.4%) 4873 (56.8%) b0.001
HDL, high density lipoprotein; SUA, serum uric acid.
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3.1. Baseline characteristics
The baseline SUA level in this population showed a Gaussian distri-
bution, and the average value [±standard deviation (SD)] was 5.78
(±1.11) mg/dL. The average SUA levels (mg/dL) of each group (±SD)
were 4.6 (±0.66), 5.8 (±0.26), and 7.0 (±0.62) at the 1st, 2nd, and
3rd tertiles, respectively. The average age and BMI (±SD) of all partici-
pants were 36.8 (±8.7) years and 22.5 (±2.8) kg/m2, respectively. In
comparison, according to the tertile of SUA level, therewere statistically
signiﬁcant trends in all parameters, except for age. There was an oppo-
site trend in high-density lipoprotein cholesterol and smoking habit
(Fig. 2, Table 1).Table 2
Baseline characteristics according to the incident hypertension.
Incident hyperten
−
Number of participants (%) 15,081 (57.0%)
Serum uric acid concentration (mg/dL) 5.67 ± 1.08
Age (years) 36.4 ± 8.9
Body mass index (kg/m2) 21.9 ± 2.5
Systolic blood pressure (mm Hg) 110.6 ± 9.7
Diastolic blood pressure (mm Hg) 66.7 ± 8.8
Total cholesterol (mg/dL) 186.4 ± 31.2
HDL cholesterol (mg/dL) 57.5 ± 13.5
Triglyceride (mg/dL) 110.4 ± 70.7
Creatinine (mg/dL) 0.93 ± 0.10
Fasting blood glucose (mg/dL) 89.3 ± 12.4
Dipstick proteinuria
Negative 14,839 (98.4%)
Trace 90 (0.6%)
≥1+ 152 (1.0%)
Smoker
Never 4090 (27.1%)
Former 2789 (18.5%)
Current 8202 (54.4%)
Alcohol intake
Habitual 4963 (32.9%)
Non-habitual 10,118 (67.1%)
HDL, high density lipoprotein.As for the baseline characteristics according to the presence of inci-
dent hypertension, mean SUA level (±SD) was 5.92 (±1.14) mg/dL in
incident hypertension and 5.67 (±1.08) mg/dL in non-hypertension.
All parameters showed statistically signiﬁcant difference (Table 2).
3.2. Serum uric acid and risk for incident hypertension
The mean follow-up period was 7.2 years, and 11,361 (43.0%) sub-
jects developed newly detected hypertension. Newly detected hyper-
tension incidence was 37.4% in the 1st tertile, 41.0% in the 2nd tertile,
and 50.8% in the 3rd tertile (log-rank test p b 0.0001; Fig. 3).
HR [95% conﬁdence interval (CI)] of incident hypertension of the 3rd
tertile in model 1 was 1.51 (1.45–1.58) and remained signiﬁcant even
when adjusting for age in model 2 (adjusted HR: 1.52, 95% CI: 1.45–sion
p+
11,361 (43.0%)
5.92 ± 1.14 b0.0001
37.3 ± 8.3 b0.0001
23.3 ± 3.0 b0.0001
118.2 ± 9.5 b0.0001
72.3 ± 9.1 b0.0001
192.7 ± 31.0 b0.0001
56.1 ± 13.6 b0.0001
123.9 ± 81.4 b0.0001
0.94 ± 0.11 0.0006
91.4 ± 12.6 b0.0001
11,083 (97.6%)
87 (0.8%)
191 (1.7%) b0.001
2788 (24.5%)
2149 (18.9%)
6424 (56.5%) b0.001
4575 (40.3%)
6786 (59.7%) b0.001
Fig. 3. Cumulative incidence of hypertension according to the tertile of the serum uric acid
concentration estimated using the Kaplan–Meier method. Mean follow-up time was
7.2 years. The number of cumulative incident hypertension episodes was 11,361
(43.0%). The blue dotted line indicates the 1st tertile group, green dash indicates the
2nd tertile group, and red solid indicates the 3rd tertile group.
Fig. 2. Histogram of serum uric acid concentration. SUA denotes serum uric acid and SD
denotes standard deviation.
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were attenuated as further adjusting for other covariates (adjusted
HR: 1.15, 95% CI: 1.10–1.21; Table 3).3.3. Subgroup analysis
3.3.1. Age
Adjusted HR in model 5 was calculated as a reference for those aged
b40 years and the lowest tertile of SUA levels. Adjusted HR was signiﬁ-
cantly higher in those aged ≥40 years than those aged b40 years (p for
interaction = 0.035; Fig. 4).Table 3
Hazard ratios for incident hypertension.
SUA tertile (mg/dL)
Hazard ratio (95% CI)
Model 1 Model 2
1st 0.1–5.3 1 (reference) 1 (reference)
2nd 5.4–6.2 1.12 (1.06–1.17) 1.13 (1.08–1.18)
3rd 6.3–11.6 1.51 (1.45–1.58) 1.52 (1.45–1.59)
Model 1, crude; Model 2, age; Model 3: Model 2 + BMI; Model 4: Model 3 + baseline BP; Mod
smoking, alcohol intake. CI, conﬁdence interval; SUA, serum uric acid.3.3.2. BMI
As a reference, in those with BMI b 25 kg/m2 and lowest tertile of
SUA, adjusted HR in model 5 was calculated. Adjusted HR was higher
in those with BMI ≥ 25 kg/m2 than those with BMI b 25 kg/m2 but not
signiﬁcant (p for interaction = 0.080; Fig. 5).
4. Discussion
In this study,we performed a large-scale long-termcohort study and
showed that SUA level is an independent predictor of incident hyper-
tension in young andmiddle-aged Japanesemen. Furthermore, the rela-
tionship was particularly strong in those aged ≥40 years.
The mechanism by which elevated SUA levels induce hypertension
remains elusive. Oxidative stress, inﬂammation, nitric oxide (NO) pro-
duction impairment, vascular endothelial dysfunction, vascular smooth
muscle proliferation, and renin angiotensin system enhancement have
been reported asmechanisms for developing hypertension by hyperuri-
cemia (Corry et al., 2008; Glantzounis et al., 2005; Kang et al., 2005a,
2005b; Khosla et al., 2005; Kono et al., 2010).
Crystallization of UA itself has also been reported to cause inﬂamma-
tion, gouty kidney, and urinary tract calculi, and progression to renal
failure (Chonchol et al., 2007; Iseki et al., 2004; Low and Stoller, 1997;
Weiner et al., 2008). Vascular disorders are important as a mechanism
of incident hypertension by hyperuricemia, and there have been two re-
ported pathways in previous studies (Battelli et al., 2014; Kang et al.,
2005a, 2005b; Neogi et al., 2012; Price et al., 2006).
Vascular disorders can be caused by active oxygen produced by xan-
thine oxidase (XO). Hypoxanthine is a UA precursor and is metabolized
to UA by XO present in the vascular endotheliumwhere the active oxy-
gen generated in theprocess inactivates NO in the vascular endothelium
and proliferates vascular smooth muscle thus promoting arteriosclero-
sis (Battelli et al., 2014; Neogi et al., 2012).
Another pathway causing vascular disorders is the mechanism by
UA itself ﬂowing into the cells via a UA transporter present in the vascu-
lar endothelial cells and vascular smoothmuscle cells. TheUA transport-
er is mainly present in the proximal tubule in addition to the vascular
smooth muscle cells (Price et al., 2006). UA causes vascular smooth
muscle cell proliferation through urate transporters (Kang et al.,
2005a, 2005b).
The vasorelaxant effect of acetylcholinewas reported to attenuate as
UA concentration increased in in vitro experiments using rat aorta
(Nakagawa et al., 2006).
In developing hypertension by hyperuricemia, two phases would be
conceived. In the ﬁrst phase, inhibition of NO production and activation
of the renin–angiotensin system by hyperuricemia causes excessive va-
soconstriction, resulting in hypertension. This process is reversible and
is a UA-dependent reaction where blood pressure can be reduced by
lowering UA (Feig, 2012; Mazzali et al., 2001; Mazzali et al., 2002).
In the second phase, when hyperuricemia persists, the proliferation
of vascular smoothmuscle cells thickens vesselwall and increases blood
pressure because of changes in the vascular structure. This step is UA in-
dependent and blood pressure does not return to the original level any-
more by lowering UA as in theﬁrst phase (Feig, 2012; Kang et al., 2005a,
2005b). In this study, a stronger relationship between SUA level and hy-
pertension developed in subjects aged ≥40 years. Long-term exposureModel 3 Model 4 Model 5
1 (reference) 1 (reference) 1 (reference)
1.04 (1.00–1.09) 1.01 (0.96–1.06) 1.01 (0.96–1.05)
1.22 (1.16–1.27) 1.16 (1.11–1.22) 1.15 (1.10–1.21)
el 5: Model 4 + total cholesterol, triglyceride, creatinine, proteinuria, fasting blood sugar,
Fig. 4. Adjusted hazard ratios stratiﬁed by age (b40 years vs. ≥40 years). Adjusted hazard ratios were calculated inModel 5. The lowest tertile of serum uric acid and age ≤ 40 years group
was used as reference. Covariates included age, body mass index, baseline blood pressure, total cholesterol, triglyceride, creatinine, proteinuria, fasting blood sugar, smoking, and alcohol
intake in Model 5.
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vessels, which could be related to higher HR in ≥40-year-old subjects
and existence of interaction between age and SUA.
On the other hand, therewas no signiﬁcant interaction between SUA
and BMI in this study. SUA and obesity may resonate each other by ac-
tivating the renin-angiotensin system (Corry et al., 2008; Goossens et
al., 2003; Reaven, 2011). In fact, the Tromsø Study in Norway, in con-
trast to our present study, demonstrated that higher baseline SUA was
associated with higher odds of developing elevated blood pressure in
overweight subjects (BMI ≥ 25 kg/m2), but not in normal-weight sub-
jects (BMI b 25 kg/m2) (Norvik et al., 2016). The subjects in the present
study were relatively thin and the average of BMI was 22.5 kg/m2.
Therefore, the signiﬁcant interaction between SUA and BMI (b25 kg/
m2 vs. ≥25 kg/m2) would not be observed. Further research of more
overweight/obese samples is needed to verify the interaction.
5. Limitations
There were some limitations to this study. Only Japanese men were
used as subjects because there was not long-term enough data for fe-
male workers; the number of female workers was limited and most fe-
male workers took one to three years maternity leave, during which
blood pressures were not followed. Blood pressure was measured only
once a year; in addition, blood pressure was not monitored at home.
Data on abdominal circumference, daily exercise, diet, stress, and family
history were not collected.
6. Conclusion
High SUA levels increases the risk of incident hypertension in young
andmiddle-aged Japanesemales without hypertension, hyperuricemia,Fig. 5. Adjusted hazard ratios stratiﬁed by bodymass index (BMI; b25 kg/m2 vs. ≥25 kg/m2). A
BMI b 25 kg/m2 group was used as reference. Covariates included age, bodymass index, baselin
smoking, and alcohol intake in Model 5.heart disease, renal disease, lipid abnormalities, and diabetes mellitus.
This association was stronger among subjects ≥40 years old.
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